Grifols SA

Grifols SA

Grifols SA

Overview
Date Founded

1940

Headquarters

Avinguda de la Generalitat, 152-158,Parc de Negocis Can Sant Joan,Sant Cugat del Vallès,Barcelona, Catalonia 08174

Type of Company

Public

Employees (Worldwide)

21.2K

Industries

Pharmaceuticals

Company Description

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Contact Data
Trying to get in touch with decision makers at Grifols SA? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Joint Chief Executive Officer & Executive Director

Joint Chief Executive Officer & Executive Director

Corporate Vice President & Chief Financial Officer

Chief Commercial Officer

Chief Human Resources Officer & Vice President

President of the Diagnostic Commercial Division

President of the Bioscience Commercial Division

President of the Bio Supplies Division

Vice President-Quality & Regulatory Affairs

President of the Diagnostic Industrial Group

Board of Directors

Chairman & Chief Executive Officer at Arrahona Optimus SL

Industry Advisor at Madison Dearborn Partners LLC

Professor at University of Washington

Joint Chief Executive Officer & Executive Director at Grifols SA

Secretary & Director at Barcelona Cartonboard S.A.U.

Chairman & Chief Executive Officer at Iron Horse Acquisition Corp.

Former Executive Director at Grifols SA

Chairman & Chief Executive Officer at Morgan Stanley SV SAU

Joint Chief Executive Officer & Executive Director at Grifols SA

Vice President at UNICEF Spanish Committee

Paths to Grifols SA
Potential Connections via
Relationship Science
You
Grifols SA
Owners & Shareholders
Details Hidden

AKO Capital LLP (AKO Capital) is an independent alternative investment management firm which was founded by Nicolai Tangen in 2005. Based in London, AKO Capital manages funds for a range of clients including institutional investors, endowments, funds of funds and high-net worth individuals.

Details Hidden

Harding Loevner invests primarily in publicly-traded global equities which seeks superior returns. Their investment philosophy emphasizes long-term investments in high quality, growing businesses, and their investment approach relies on in-depth fundamental research including analysis of the competitive structure of global industries and the competitive position of individual companies. The firm undertakes in-depth fundamental company research and industry analysis to identify and value companies that exhibit four key quality-growth criteria: competitive advantage, quality management, financial strength, and sustainable growth. Portfolio managers construct each model portfolio informed by analysts' recommendations and impact on portfolio risk. Harding Loevner builds model portfolios from the bottom-up, so the sector and country allocations in our strategies are primarily the result of individual stock selection, and not a top-down country or sector allocation process.

Details Hidden

FIL-UK is an active, growth-oriented manager which aims to achieve long-term capital appreciation through a bottom-up approach. They focus on individual companies, seeking to identify fundamental value in stocks. They uses a wide variety of investment strategies in managing client assets. FIL-UK conducts fundamental research, focusing on business franchise, trading environment, valuation, and management. Top-down considerations complement their approach, with particular attention paid to political, environmental and social issues likely to impact a company's potential. Positions are usually significant in size and long-term in duration. FIL-UK is heavily research-oriented and does not rely on sell-side research. Fund managers and analysts aim at personally visiting the companies in which they invest at least twice a year. Asset management is team-oriented and portfolios are peer-reviewed.

Recent Transactions
Details Hidden

Grifols SA purchases Interstate Blood Bank, Inc.

Details Hidden

Grifols SA purchases Juvé & Camps SA

Details Hidden

Shanghai RAAS Blood Products Co., Ltd. purchases Grifols Diagnostic Solutions, Inc. from Grifols SA

Transaction Advisors
Legal Advisor

Advised onGrifols SA purchases Talecris Biotherapeutics Holdings Corp. from Cerberus Capital Management LP

Legal Advisor

Advised onGrifols SA purchases Talecris Biotherapeutics Holdings Corp. from Cerberus Capital Management LP

Investment Advisor

Advised onGrifols SA purchases Talecris Biotherapeutics Holdings Corp. from Cerberus Capital Management LP

Associate

Advised onGrifols SA, Grifols Shared Services North America, Inc. purchase Goetech LLC

Legal Advisor

Advised onGrifols SA purchases Novartis AG /Blood Transfusion Diagnostics Unit from Novartis AG resulting in a new company Grifols Chiron Diagnostics Corp.

Legal Advisor

Advised onGrifols SA purchases Novartis AG /Blood Transfusion Diagnostics Unit from Novartis AG resulting in a new company Grifols Chiron Diagnostics Corp.

Advisors & Consultants
Legal Advisor

Partner at Proskauer Rose LLP

Legal Advisor

Partner at Proskauer Rose LLP

Legal Advisor

Partner at Proskauer Rose LLP

Clients

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial and commercial products and services. It operates through the following five segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician's offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products and services that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as to improve the aesthetics of the human smile. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.

Henry Schein, Inc., a FORTUNE 500® company and a member of the NASDAQ 100® Index, is the largest provider of health care products and services to medical, dental, and veterinary office-based practitioners. The Company is one of Fortune Magazine's "World’s Most Admired Companies", and is ranked number 1 in its industry in social responsibility and global competitiveness. Now more than ever, health care providers require specialized products and services to operate their practices efficiently. We offer an extensive selection of dental supplies, medical supplies, pharmaceuticals, vaccines, equipment, software technology, and much more. Our portfolio of practice solutions is designed to support our customers and to successfully meet their business goals and achieve optimal patient satisfaction

Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Cardiovascular and Neuromodulation Products, and Other. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Vascular Products segment trades coronary, endovascular, structural heart, vessel closure, and other medical device products. The Other segment comprises of Abbott Medical Optics. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Key Stats and Financials As of 2018
Market Capitalization
$20.5B
Total Enterprise Value
$21.4B
Earnings Per Share
$0.87
EBITDAMargin
27.25%
Total Equity
$4.7B
Total Debt
$6.28B
Revenue
$4.49B
Net Profit
$597M
EBITDA
$1.22B
Debt TEV
0.29x
Enterprise Value Sales
4.77x
TEVNet Income
35.87x
Enterprise Value EBITDAOperating
17.5x
Three Year Compounded Annual Growth Rate Of Revenue
4.47%
Five Year Compounded Annual Growth Rate Of Revenue
10.35%
Investments
Details Hidden

Araclon Biotech SL researches and develops therapies and diagnostic methods for Alzheimer's disease. Its research areas include early diagnosis of Alzheimer's disease; therapy for Alzheimer's disease; development of a predictive test for the Alzheimer's disease in asymptomatic individuals; and development of therapy for Parkinson's disease. The company was founded on January 27, 2004 and is headquartered in Zaragoza, Spain.

Details Hidden

Singulex, Inc. provides biotechnological research and development services. It also provides instrumentation and immunoassays with the requisite sensitivity and specificity to enable biomarker discovery and validation for drug safety and efficacy. The company was founded by Robert S. Puskas in November 1997 and is headquartered in Alameda, CA.

Details Hidden

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Suppliers
Hologic, Inc. Medical Support Services | MARLBOROUGH, MA

Hologic, Inc. (Nasdaq: HOLX) is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products dedicated to serving the healthcare needs of women throughout the world. At Hologic, we are on a mission: to help women everywhere lead longer, healthier lives. It is our reason for being and the single focus of every breakthrough we pursue, every solution we design, every investment we make. Hologic is a market leader in mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging, and molecular diagnostic products including human papillomavirus (HPV) testing and reagents for a variety of DNA and RNA analysis applications. We are proud of our achievements and conscious of the responsibility that our leadership position brings with it. We believe that the health issues facing women today deserve and demand the singular dedication of a passionate company. Our core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health

Aradigm Corp. Biotechnology | HAYWARD, CALIFORNIA

Aradigm Corp. operates as a pharmaceutical company, which focuses on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases by pulmonologists. Its technologies include diabetes and pain management, AERx essence devices. The company was founded in 1991 and is headquartered in Hayward, CA.

Cumberland Pharmaceuticals, Inc. Biotechnology | Nashville, Tennessee

Cumberland Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Hepatoren, Vaprisol, Boxaban, Vasculan, Ethyol, Portaban, and Totect. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Competitors
CSL Limited Biotechnology - Parkville, VIC

CSL Ltd. is a biopharmaceutical company, which engages in the manufacture, marketing, and distribution of biopharmaceutical and allied products. It operates through the CSL Behring and Seqirus segments. The CSL Behring segment provides plasma therapies and conducts early stage research on plasma and non plasma therapies. The Seqirus segment involves in the production of non-plasma biotherapeutic products and develops influenza related products. The company was founded on November 2, 1961 and is headquartered in Parkville, Australia.

Kamada Ltd. Biotechnology - Ness Ziona, HM

Kamada is a biopharmaceutical company engaged in developing, producing and marketing of specialty life-saving therapeutics, using a unique protein purification technology. Kamada´s product line consists of more than 10 injectable pharmaceutical products which are marketed in more than 15 countries worldwide. The Company's pharmaceuticals are produced in its state-of-the-art, cGMP-compliant, FDA-approved, large scale production facility. Kamada’s flagship product is Glassia®; an FDA approved intravenous (IV) Alpha-1 Antitrypsin (AAT) protein, for the treatment of AAT Deficiency. Glassia® is a high purity, ready to use and stabilizer free augmentation treatment .Kamada has a strategic agreement with Baxter for US marketing, distribution and licensing of Glassia®. Kamada’s second generation AAT product is an inhaled (IH) version. This product is already in advanced stages of clinical development for the treatment of AAT Deficiency. Other potential indications for AAT (IV or IH) include bronchiectasis, cystic fibrosis, COPD as well as type-1 diabetes for which the Company started a clinical trial. Sided to its capabilities to manufacture specialty proteins, Kamada has developed a platform technology for the production of specific immunoglobulins (IgGs). Kamada´s unique know-how and capabilities enable it to seek for new business opportunities and offer a wide scope of pharma-oriented services, including: R&D of new biopharmaceuticals, large scale production of high quality biopharmaceuticals, formulation and aseptic filling, registration and marketing. Over the years Kamada has established its presence in the pharma industry worldwide. Kamada’s mission is to develop, manufacture and provide high quality, specialty pharmaceuticals to patients, in order to support better quality of life and save lives. Founded in 1990, Kamada successfully completed an Initial Public Offering in 2005.The company is traded at the Tel Aviv Stock Exchange (KMDA). Kamada's headquarters is located in the Weizmann Science Park in Nes Ziona, Israel

Takeda Pharmaceutical Co., Ltd. Pharmaceuticals - Osaka, OS

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Awards & Honors
Rank #64
2014
Forbes - World's 100 Most Innovative Companies
Sponsored by Forbes Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Grifols SA. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Grifols SA's profile does not indicate a business or promotional relationship of any kind between RelSci and Grifols SA.